Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP.
Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...
Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...
(RTTNews) - Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi Biotec B.V. & Co. KG, which may appeal the Court's ...
May 7 (Reuters) - Bio-Techne (TECH.O), opens new tab on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other ...
We think Bio-Techne’s moat has been constructed from two interrelated strengths: first, market-leading product quality in its protein portfolio, which has allowed for decades-long pricing leadership; ...
Bio-Techne (NASDAQ:TECH) will release its quarterly earnings report on Wednesday, 2025-11-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Bio-Techne to report ...
Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. In 2013, Bio-Techne ...
Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results